Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord OvestAlfredo Falcone, Gianluca Masi|Journal of Clinical Oncology|2007Cited by 1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Alfredo Falcone, Luca Boni et al.|The Lancet Oncology|2015Cited by 1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerFotios Loupakis, Alfredo Falcone, Chiara Cremolini et al.|New England Journal of Medicine|2014Cited by 1.1k
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanChiara Cremolini, Daniele Santini, Daniele Rossini et al.|JAMA Oncology|2018Cited by 418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322